Journal of Clinical Research in Paramedical Sciences

Published by: Kowsar

Preparation of 177Lu-Rituximab and Comparison with 131I-Rituximab Radiolabeled with Chloramine-T Method

Fariba Johari Daha 1 , * , Samira Rasaneh 2 and Saleh Salehi Zahabi 3 , 4
Authors Information
1 Radiopharmacey and Radioisotope Department, Application Radiation School, Nuclear Sciences and Technology Research Institute, Tehran, Iran
2 School of Allied Medical Sciences, Lorestan University of Medical Sciences, Khorramabad, Iran
3 Radiology and Nuclear Medicine Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
4 Clinical Research Development Center, Taleghani and Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • Journal of Clinical Research in Paramedical Sciences: 7 (2); e87181
  • Published Online: December 31, 2018
  • Article Type: Research Article
  • Received: December 8, 2018
  • Accepted: December 26, 2018
  • DOI: 10.5812/jcrps.87181

To Cite: Johari Daha F, Rasaneh S, Salehi Zahabi S. Preparation of 177Lu-Rituximab and Comparison with 131I-Rituximab Radiolabeled with Chloramine-T Method, J Clin Res Paramed Sci. Online ahead of Print ; 7(2):e87181. doi: 10.5812/jcrps.87181.

Copyright © 2018, Journal of Clinical Research in Paramedical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Kowalsky RJ, Falen SW. Radiopharmaceutical in nuclear pharmacy and nuclear medicine. Washingtone DC: The American Pharmacists Association; 2004.
  • 2. Rasaneh S, Rajabi H, Babaei MH, Daha FJ, Salouti M. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol. 2009;36(4):363-9. doi: 10.1016/j.nucmedbio.2009.01.015. [PubMed: 19423003].
  • 3. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2004;59(5):1274-87. doi: 10.1016/j.ijrobp.2004.02.065. [PubMed: 15275710].
  • 4. Vose JM. Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist. 2004;9(2):160-72. doi: 10.1634/theoncologist.9-2-160. [PubMed: 15047920].
  • 5. Johari Doha F, Rahmani S, Rikhtechi P, Rasaneh S, Sheikholislam Z, Shahhosseini S. Development of DOTA-Rituximab to be labeled with (90)Y for radioimmunotherapy of B-cell non-hodgkin lymphoma. Iran J Pharm Res. 2017;16(2):619-29. [PubMed: 28979315]. [PubMed Central: PMC5603870].
  • 6. Rasaneh S, Rajabi H, Babaei MH, Johari Doha F. Synthesis and biodistribution studiesof 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model. J Label Compound Radiopharm. 2010;53(9):575-9. doi: 10.1002/jlcr.1780.
  • 7. Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR. Antitenascin antibody 81C6 armed with 177Lu: In vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol. 2007;34(2):173-83. doi: 10.1016/j.nucmedbio.2006.11.003. [PubMed: 17307125].
  • 8. Brady ED, Chong HS, Milenic DE, Brechbiel MW. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. Nucl Med Biol. 2004;31(6):795-802. doi: 10.1016/j.nucmedbio.2004.04.004. [PubMed: 15246371].
  • 9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75. [PubMed: 14907713].
  • 10. Rasaneh S, Rajabi H, Hossein Babaei M, Johari Daha F. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines. Appl Radiat Isot. 2010;68(10):1964-6. doi: 10.1016/j.apradiso.2010.05.004. [PubMed: 20537546].
  • 11. Forrer F, Chen J, Fani M, Powell P, Lohri A, Muller-Brand J, et al. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging. 2009;36(9):1443-52. doi: 10.1007/s00259-009-1120-2. [PubMed: 19350237].
  • 12. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PJ. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72(1):77-89. doi: 10.1016/0022-1759(84)90435-6. [PubMed: 6086763].
  • 13. Johari Daha F, Rasaneh S, Zoghi M, Niazi A. [Preparation, quality control, and immunoreactivity study of 131I-Rituximab by Chloramine-T]. J Sci. 2013;23:5-12. Persian.
  • 14. Rasaneh S, Dadras MR. The potential of SOCTA as a chelator for radiolabeling of trastuzumab with 99mTc. J Radioanalyt Nucl Chem. 2015;307(2):1353-7. doi: 10.1007/s10967-015-4314-z.
  • 15. Ali SA, Warren SD, Richter KY, Badger CC, Eary JF, Press OW, et al. Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate adducts. Cancer Res. 1990;50(3 Suppl):783s-8s. [PubMed: 2297724].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments